C8166
|
EC50 |
0.0027 μM
Compound: efavirenz
|
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
|
[PMID: 19170521]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
|
[PMID: 27039251]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
|
[PMID: 27390064]
|
CCRF-CEM
|
EC50 |
|
Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
|
[PMID: 21366296]
|
CCRF-CEM
|
EC50 |
> 10000 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
|
[PMID: 25418038]
|
CCRF-CEM
|
EC50 |
> 10000 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
|
[PMID: 24769348]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells by coulter counter analysis
Cytotoxicity against human CEM cells by coulter counter analysis
|
[PMID: 21366296]
|
CCRF-CEM
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
|
[PMID: 21366296]
|
CCRF-CEM
|
EC50 |
1.5 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
|
[PMID: 25418038]
|
CCRF-CEM
|
EC50 |
1.5 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
|
[PMID: 24769348]
|
CEM-SS
|
EC50 |
0.005 μM
Compound: efavirenz
|
Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
|
[PMID: 17803290]
|
CEM-SS
|
CC50 |
0.55 μM
Compound: Efavirenz
|
Cytotoxicity against human CEM-SS cells by MTS assay
Cytotoxicity against human CEM-SS cells by MTS assay
|
10.1039/C4MD00282B
|
CEM-SS
|
EC50 |
0.92 nM
Compound: Efavirenz
|
Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
|
10.1039/C4MD00282B
|
HEK-293T
|
CC50 |
> 30 μM
Compound: Efavirenz
|
Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
|
[PMID: 32004936]
|
HEK-293T
|
EC50 |
0.0005 μM
Compound: efavirenz
|
Antiviral activity against HIV in HEK293T cells after 48 hrs
Antiviral activity against HIV in HEK293T cells after 48 hrs
|
[PMID: 17035019]
|
HEK-293T
|
IC50 |
|
Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
|
[PMID: 27484516]
|
HEK-293T
|
CC50 |
10 μM
Compound: efavirenz
|
Cytotoxicity against HEK293T cells after 48 hrs
Cytotoxicity against HEK293T cells after 48 hrs
|
[PMID: 17035019]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 25072874]
|
HEK-293T
|
IC50 |
|
Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
|
[PMID: 27484516]
|
HEK-293T
|
EC50 |
|
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
|
[PMID: 22148316]
|
HeLa
|
EC50 |
|
Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
|
[PMID: 17646410]
|
HeLa
|
EC50 |
0.0001 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
|
[PMID: 17967909]
|
HeLa
|
EC50 |
|
Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
[PMID: 19805571]
|
HeLa
|
EC50 |
|
Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
[PMID: 19805571]
|
HeLa
|
EC50 |
|
Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
[PMID: 19805571]
|
HeLa
|
EC50 |
|
Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
|
[PMID: 19805571]
|
HeLa
|
EC50 |
|
Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
|
[PMID: 17646410]
|
HeLa
|
IC50 |
0.4 nM
Compound: efavirenz, EFV
|
Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
0.6 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
0.8 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
0.8 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
0.9 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1.2 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1.2 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1.3 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1.8 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
1198 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
140 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
154 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
17 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
2 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
2.3 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
2.7 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
21 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
3 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
44 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
485 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
5.9 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
7.2 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
89 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
HeLa
|
IC50 |
94 nM
Compound: efavirenz, EFV
|
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
|
[PMID: 18665583]
|
MRC5
|
IC50 |
25.84 μM
Compound: Efavirenz
|
Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
|
[PMID: 25199582]
|
MRC5
|
IC50 |
8.56 μM
Compound: Efavirenz
|
Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
|
[PMID: 25199582]
|
MT2
|
CC50 |
> 0.1 μM
Compound: Evafirenz
|
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
|
[PMID: 20304641]
|
MT2
|
CC50 |
> 0.1 μM
Compound: Evafirenz
|
Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
|
[PMID: 20304641]
|
MT2
|
CC50 |
> 0.1 μM
Compound: Evafirenz
|
Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
|
[PMID: 20304641]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
|
[PMID: 25408842]
|
MT2
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
[PMID: 23937980]
|
MT2
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
|
[PMID: 23899617]
|
MT2
|
EC50 |
0.002 μM
Compound: Evafirenz
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
|
[PMID: 20304641]
|
MT2
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
|
[PMID: 23298809]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
0.005 nM
Compound: EFV, DMP-266, L-743, L-726
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
|
[PMID: 20660667]
|
MT2
|
EC50 |
|
Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
|
[PMID: 25408842]
|
MT2
|
EC50 |
0.01 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
[PMID: 23937980]
|
MT2
|
EC50 |
0.01 μM
Compound: Evafirenz
|
Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
|
[PMID: 20304641]
|
MT2
|
EC50 |
0.01 μM
Compound: Efavirenz
|
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
|
[PMID: 23298809]
|
MT2
|
EC50 |
|
Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
|
[PMID: 25408842]
|
MT2
|
EC50 |
0.03 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
[PMID: 23937980]
|
MT2
|
EC50 |
0.03 μM
Compound: Evafirenz
|
Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
|
[PMID: 20304641]
|
MT2
|
EC50 |
0.03 μM
Compound: Efavirenz
|
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
|
[PMID: 23298809]
|
MT2
|
EC50 |
0.05 nM
Compound: EFV, DMP-266, L-743, L-726
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
|
[PMID: 20660667]
|
MT2
|
EC50 |
0.5 nM
Compound: EFV, DMP-266, L-743, L-726
|
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
|
[PMID: 20660667]
|
MT2
|
EC50 |
|
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
|
[PMID: 21745701]
|
MT2
|
EC50 |
15 μM
Compound: Efavirenz
|
Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
|
[PMID: 35175760]
|
MT2
|
CC50 |
15 μM
Compound: Efavirenz
|
Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
|
[PMID: 27485603]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 25408842]
|
MT2
|
CC50 |
15 μM
Compound: Efavirenz
|
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
|
[PMID: 23899617]
|
MT2
|
CC50 |
15 μM
Compound: Efavirenz
|
Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
|
[PMID: 22081993]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
|
[PMID: 17918923]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
|
[PMID: 19104010]
|
MT4
|
EC50 |
|
Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
|
[PMID: 19007201]
|
MT4
|
EC50 |
|
Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
10.1007/s00044-008-9149-5
|
MT4
|
CC50 |
> 0.00633 μM
Compound: EFV
|
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 28481112]
|
MT4
|
CC50 |
> 0.3 μM
Compound: EFV, efavirenz
|
Cytotoxicity against MT4 cells after 4 days by MTT method
Cytotoxicity against MT4 cells after 4 days by MTT method
|
[PMID: 17910429]
|
MT4
|
CC50 |
> 0.32 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 19140683]
|
MT4
|
CC50 |
> 0.32 μM
Compound: Efavirenz
|
Cytotoxicity against MT4 cells by MTT assay
Cytotoxicity against MT4 cells by MTT assay
|
[PMID: 16621553]
|
MT4
|
CC50 |
|
Cytotoxicity against MT4 cells by MTT method
Cytotoxicity against MT4 cells by MTT method
|
[PMID: 16335924]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22652226]
|
MT4
|
IC50 |
> 10 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
EC50 |
> 10 μM
Compound: EFV, efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
|
[PMID: 17910429]
|
MT4
|
EC50 |
> 10 μM
Compound: efavirenz
|
Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
|
[PMID: 19469474]
|
MT4
|
EC50 |
|
Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
|
[PMID: 19007201]
|
MT4
|
IC50 |
> 100 nM
Compound: Efavirenz
|
Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
|
[PMID: 20829038]
|
MT4
|
IC50 |
> 100 nM
Compound: Efavirenz
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
|
[PMID: 20829038]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
|
[PMID: 22712652]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 32883642]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
|
[PMID: 28628334]
|
MT4
|
CC50 |
> 15839 nM
Compound: EFV, DMP-266
|
Cytotoxic activity against human MT4 cells by MTT assay
Cytotoxic activity against human MT4 cells by MTT assay
|
[PMID: 25418038]
|
MT4
|
CC50 |
> 15839 nM
Compound: EFV, DMP-266
|
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
|
[PMID: 24769348]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
|
[PMID: 31091477]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 23415090]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 29353724]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
|
[PMID: 24933420]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 18630898]
|
MT4
|
CC50 |
> 3.16 μM
Compound: 3; EFV
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30606670]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30525601]
|
MT4
|
EC50 |
> 31.68 μM
Compound: Efavirenz
|
Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
> 31.68 μM
Compound: Efavirenz
|
Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
> 31.68 μM
Compound: Efavirenz
|
Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
> 317 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
|
[PMID: 25418038]
|
MT4
|
EC50 |
> 317 nM
Compound: EFV, DMP-266
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
|
[PMID: 24769348]
|
MT4
|
CC50 |
> 40196 nM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
|
[PMID: 35175760]
|
MT4
|
CC50 |
> 6 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells after 5 days
Cytotoxicity against human MT4 cells after 5 days
|
[PMID: 19616956]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 25707013]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 25626145]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 34496571]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33352387]
|
MT4
|
CC50 |
> 6.3 μM
Compound: 3; EFV
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 33340914]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
|
[PMID: 27750153]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 27267005]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
|
[PMID: 24680058]
|
MT4
|
CC50 |
> 6.3 μM
Compound: EFV, DMP266
|
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 24275349]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 24239481]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22575532]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22405288]
|
MT4
|
CC50 |
> 6.3 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
|
[PMID: 31767136]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 25150090]
|
MT4
|
CC50 |
> 6.3 μM
Compound: 3, EFV
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 24794751]
|
MT4
|
CC50 |
|
Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
|
[PMID: 23098609]
|
MT4
|
CC50 |
|
Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
|
[PMID: 23098609]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 23084898]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells by MTT assay
Cytotoxicity against mock-infected human MT4 cells by MTT assay
|
[PMID: 22883027]
|
MT4
|
CC50 |
> 6.3 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells after 5 days MTT assay
Cytotoxicity against human MT4 cells after 5 days MTT assay
|
[PMID: 27112451]
|
MT4
|
CC50 |
> 6.33 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 21824782]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 35073089]
|
MT4
|
CC50 |
|
Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
|
[PMID: 33851529]
|
MT4
|
CC50 |
> 6.33 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 29291935]
|
MT4
|
CC50 |
> 6.33 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 28559060]
|
MT4
|
CC50 |
> 6.33 μM
Compound: 3; EFV
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
|
[PMID: 35640327]
|
MT4
|
CC50 |
|
Cytotoxicity against mock infected human MT4 cells by MTT assay
Cytotoxicity against mock infected human MT4 cells by MTT assay
|
[PMID: 34197708]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33567378]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
|
[PMID: 19628308]
|
MT4
|
CC50 |
|
Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
|
10.1007/s00044-009-9220-x
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 29670703]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 19643613]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
|
[PMID: 31421633]
|
MT4
|
CC50 |
|
Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
|
[PMID: 26994843]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 20307984]
|
MT4
|
CC50 |
> 6.34 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 33979774]
|
MT4
|
CC50 |
> 6.34 μM
Compound: 3; EFV
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 32977301]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 32712537]
|
MT4
|
CC50 |
|
Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 31935327]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 31735575]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 31714780]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30721060]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
|
[PMID: 29635166]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 29559197]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 29534929]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 28254696]
|
MT4
|
CC50 |
> 6.34 μM
Compound: Efavirenz
|
Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
|
[PMID: 26385446]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
|
[PMID: 25240095]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
|
[PMID: 24602795]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 23707918]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 23707918]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22591854]
|
MT4
|
CC50 |
|
Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
|
[PMID: 21683601]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
|
10.1039/C3MD00247K
|
MT4
|
CC50 |
|
Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
|
10.1039/C3MD00028A
|
MT4
|
CC50 |
|
Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
|
10.1039/C3MD00028A
|
MT4
|
CC50 |
> 6.34 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35649164]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34432448]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 33279288]
|
MT4
|
CC50 |
|
Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 28987601]
|
MT4
|
CC50 |
> 6.34 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells measured by MTT assay
Cytotoxicity against human MT4 cells measured by MTT assay
|
[PMID: 22037050]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days MTT assay
Cytotoxicity against human MT4 cells after 5 days MTT assay
|
[PMID: 25537532]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
|
[PMID: 34090079]
|
MT4
|
CC50 |
> 6.35 μM
Compound: 3; EFV
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 31434039]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 32200201]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
|
[PMID: 25907370]
|
MT4
|
CC50 |
> 63 μM
Compound: Efavirenz, Sustiva
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 21903401]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 20570527]
|
MT4
|
CC50 |
> 6336 nM
Compound: 3, EFV
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
|
[PMID: 26276435]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
|
[PMID: 25935383]
|
MT4
|
CC50 |
|
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 27541578]
|
MT4
|
CC50 |
|
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 34890994]
|
MT4
|
CC50 |
> 9 μM
Compound: Efavirenz
|
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
|
[PMID: 28314598]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 20598556]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
|
[PMID: 27501911]
|
MT4
|
EC50 |
0.0007 μM
Compound: 2; EFV
|
Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
|
[PMID: 26804933]
|
MT4
|
EC50 |
0.0009 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
|
[PMID: 20097079]
|
MT4
|
EC50 |
0.0009 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
|
[PMID: 19616956]
|
MT4
|
EC50 |
0.0009 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
|
[PMID: 18585918]
|
MT4
|
EC50 |
0.00095 μM
Compound: Efavirenz
|
Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
IC50 |
0.001 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
EC50 |
0.001 μM
Compound: Efavirenz
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19140683]
|
MT4
|
ED50 |
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
|
[PMID: 18842407]
|
MT4
|
EC50 |
0.001 μM
Compound: Efavirenz
|
Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
|
[PMID: 16621553]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
|
[PMID: 16335924]
|
MT4
|
EC50 |
0.001 μM
Compound: efavirenz
|
Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
|
[PMID: 17803290]
|
MT4
|
EC50 |
0.001 μM
Compound: Efavirenz
|
Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
|
[PMID: 27371922]
|
MT4
|
EC50 |
0.0016 μM
Compound: Efavirenz
|
Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
0.0018 μM
Compound: 2; EFV
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
|
[PMID: 26804933]
|
MT4
|
EC50 |
0.0019 μM
Compound: Efavirenz
|
Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
IC50 |
0.002 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
|
[PMID: 26479028]
|
MT4
|
EC50 |
0.002 μM
Compound: efavirenz
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 26358281]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
|
[PMID: 25913116]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
|
[PMID: 25014745]
|
MT4
|
EC50 |
0.002 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.002 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24489455]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 22884523]
|
MT4
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 22513121]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 22047799]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 19775780]
|
MT4
|
EC50 |
0.002 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
|
[PMID: 26119992]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 27234889]
|
MT4
|
EC50 |
0.003 μM
Compound: Efavirenz, Sustiva
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
|
[PMID: 21903401]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
|
[PMID: 20570527]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 20307984]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 19781821]
|
MT4
|
EC50 |
0.003 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19140683]
|
MT4
|
EC50 |
0.003 μM
Compound: efavirenz
|
Antiviral activity against HIV1 3B infected in MT4 cells by MTT
Antiviral activity against HIV1 3B infected in MT4 cells by MTT
|
[PMID: 18267363]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
|
[PMID: 22652226]
|
MT4
|
EC50 |
0.003 μM
Compound: efavirenz
|
Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
|
[PMID: 19469474]
|
MT4
|
EC50 |
0.004 μM
Compound: Efavirenz
|
Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
|
[PMID: 15634015]
|
MT4
|
EC50 |
0.004 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.004 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.004 μM
Compound: EFV, efavirenz
|
Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
|
[PMID: 17910429]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 27234889]
|
MT4
|
EC50 |
0.004 μM
Compound: efavirenz
|
Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
|
[PMID: 19469474]
|
MT4
|
IC50 |
0.004 μM
Compound: Efavirenz
|
Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
|
[PMID: 15149669]
|
MT4
|
EC50 |
|
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
|
10.1007/s00044-009-9220-x
|
MT4
|
EC50 |
|
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
|
[PMID: 21683601]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
|
[PMID: 19628308]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
|
[PMID: 19643613]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 26443549]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 25082514]
|
MT4
|
EC50 |
0.005 μM
Compound: Efavirenz
|
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 21824782]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 26802545]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 22575532]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 23098609]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
|
[PMID: 23084898]
|
MT4
|
EC50 |
0.005 μM
Compound: Efavirenz
|
Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
|
[PMID: 27371922]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
|
[PMID: 25150090]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
|
[PMID: 26994843]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 26802545]
|
MT4
|
EC50 |
|
Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
|
[PMID: 25907370]
|
MT4
|
EC50 |
0.0054 μM
Compound: Efavirenz
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 22037050]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
|
10.1039/C3MD00028A
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 21872971]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 24602795]
|
MT4
|
EC50 |
0.006 μM
Compound: Efavirenz
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 27112451]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25707013]
|
MT4
|
EC50 |
0.006 μM
Compound: 3, EFV
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
|
[PMID: 24794751]
|
MT4
|
EC50 |
0.006 μM
Compound: EFV, efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
|
[PMID: 17910429]
|
MT4
|
EC50 |
0.006 μM
Compound: Efavirenz
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
|
[PMID: 24457088]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25537532]
|
MT4
|
EC50 |
0.0063 μM
Compound: Efavirenz
|
Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 26385446]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 25240095]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 24055077]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 27267005]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 26802545]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
|
[PMID: 24239481]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
|
[PMID: 23415090]
|
MT4
|
EC50 |
|
Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
|
[PMID: 24933420]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18630898]
|
MT4
|
EC50 |
0.0074 μM
Compound: EFV, DMP266
|
Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
|
[PMID: 24275349]
|
MT4
|
EC50 |
0.008 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19140683]
|
MT4
|
ED50 |
|
Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
|
[PMID: 18842407]
|
MT4
|
EC50 |
|
Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
|
10.1039/C3MD00247K
|
MT4
|
EC50 |
|
Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24134904]
|
MT4
|
EC50 |
0.01 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
|
Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 19775780]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 23707918]
|
MT4
|
EC50 |
0.01 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 19058881]
|
MT4
|
EC50 |
0.01 μM
Compound: table 6,efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18226533]
|
MT4
|
EC50 |
0.01 μM
Compound: efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18226532]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
|
[PMID: 24933420]
|
MT4
|
EC50 |
0.015 μM
Compound: Efavirenz
|
Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
|
[PMID: 23415090]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
|
[PMID: 18954921]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
|
[PMID: 24680058]
|
MT4
|
IC50 |
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 24952305]
|
MT4
|
EC50 |
0.025 μM
Compound: Efavirenz
|
Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
|
[PMID: 15634015]
|
MT4
|
EC50 |
0.037 μM
Compound: 2; EFV
|
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
|
[PMID: 26804933]
|
MT4
|
IC50 |
0.04 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
IC50 |
0.04 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
IC50 |
0.04 μM
Compound: Efavirenz
|
Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
|
[PMID: 14643315]
|
MT4
|
EC50 |
0.04 μM
Compound: table 6,efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18226533]
|
MT4
|
EC50 |
0.04 μM
Compound: efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18226532]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
|
[PMID: 18630898]
|
MT4
|
EC50 |
0.049 μg/mL
Compound: Efavirenz
|
Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
|
[PMID: 26385446]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 21872971]
|
MT4
|
EC50 |
0.057 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
|
[PMID: 19140683]
|
MT4
|
EC50 |
0.057 μM
Compound: Efavirenz
|
Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
|
[PMID: 16621553]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
|
[PMID: 16335924]
|
MT4
|
EC50 |
0.058 μM
Compound: 2; EFV
|
Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
|
[PMID: 26804933]
|
MT4
|
EC50 |
0.06 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
|
[PMID: 24805780]
|
MT4
|
EC50 |
|
Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 19775780]
|
MT4
|
EC50 |
0.08 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.08 μM
Compound: EFV, efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
|
[PMID: 17910429]
|
MT4
|
EC50 |
0.086 μM
Compound: Efavirenz
|
Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
|
[PMID: 18541726]
|
MT4
|
EC50 |
0.09 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
0.09 μM
Compound: EFV, efavirenz
|
Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
|
[PMID: 17910429]
|
MT4
|
EC50 |
0.1 μM
Compound: EFV, DMP266, L-743,726
|
Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 24805780]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 26802545]
|
MT4
|
EC50 |
0.101 μM
Compound: Efavirenz
|
Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
|
[PMID: 27371922]
|
MT4
|
EC50 |
|
Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
|
[PMID: 21872971]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 20598556]
|
MT4
|
EC50 |
|
Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 26802545]
|
MT4
|
ED50 |
|
Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
|
[PMID: 18842407]
|